The U.S. Food and Drug Administration and a panel of its outside advisers have expressed concerns over Pfizer’s “unblinding” plan, saying it could make it harder to continue collecting data on safety and effectiveness needed to win full FDA approval of the vaccine.
from Top World News- News18.com https://ift.tt/3pB7vgU
No comments:
Post a Comment